文献速递糖尿病肥胖与代谢综合征

妊娠糖尿病向2型糖尿病转变的新型预测生物标志物及早期病理生理机制

The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes.
PubMed 文献 · Diabetologia · 2019-01-15

本研究基于有妊娠糖尿病(GDM)史女性的前瞻性队列,在产后6-9周基线时对55例 incident 2型糖尿病病例与85例匹配对照进行靶向脂质组学分析(约1100种脂质代谢物)。机器学习优化决策树模型构建了7种脂质代谢物的预测特征,AUC达0.92(敏感性87%,特异性93%,准确率91%),并发现α-亚麻酸/亚油酸代谢和脂肪酸生物合成上调、鞘脂代谢下调与未来2型糖尿病风险相关;抑制小鼠胰岛和Min6细胞中鞘脂代谢可损害葡萄糖刺激的胰岛素分泌。

要点

  • 基于产后6-9周血浆脂质组学构建的7种脂质代谢物特征可预测GDM后2型糖尿病,AUC 0.92。
  • 鞘脂代谢下调与GDM向2型糖尿病转变相关,抑制胰岛鞘脂代谢损害葡萄糖刺激的胰岛素分泌。
  • α-亚麻酸/亚油酸代谢和脂肪酸生物合成上调与未来2型糖尿病风险强烈相关。

核心结论

  • 研究揭示了一种新型预测特征,并将鞘脂减少与GDM向2型糖尿病转变的病理生理机制相关联。
  • 在胰岛中减弱鞘脂代谢会损害葡萄糖刺激的胰岛素分泌。

研究设计与样本

  • 研究采用特征明确的前瞻性队列,纳入有GDM妊娠史的女性,均在产后6-9周(基线)入组,经2小时75g OGTT确认无糖尿病,并每年持续检测2型糖尿病(随访2年)。
  • 采用巢式配对病例对照设计,对基线血浆样本进行大规模靶向脂质组学研究,分析约1100种脂质代谢物,其中55例 incident 病例与85例非病例对照匹配。
  • 研究还进行了体内和体外实验以探究潜在病理生理机制。

主要发现

  • 机器学习优化以决策树形式揭示了7种脂质代谢物的2型糖尿病预测特征,判别能力(AUC)为0.92(敏感性87%,特异性93%,准确率91%)。
  • 该特征具有高度稳健性,包括在高置信阈值(1.0)和二元输出下进行45折交叉验证,共同最小化数据过拟合和偏倚选择的机会。
  • 对差异表达的脂质代谢物通路同步分析发现,α-亚麻酸/亚油酸代谢上调(FDR 0.002)和脂肪酸生物合成上调(FDR 0.005)以及鞘脂代谢下调(FDR 0.009)与未来发生2型糖尿病的风险强烈相关。
  • 使用药理学抑制剂fumonisin B1(FB1)和myriocin在小鼠胰岛和Min6 K8细胞(一种胰腺β细胞样细胞系)中下调鞘脂代谢,显著损害葡萄糖刺激的胰岛素分泌,但对全身葡萄糖稳态或胰岛素敏感性无显著影响。

临床怎么用

  • 产后早期(6-9周)血浆脂质组学特征可能用于识别GDM后未来2型糖尿病高风险女性,以便及时干预预防或延缓2型糖尿病。
  • 鞘脂代谢通路可能作为干预新靶点,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Gestational diabetes mellitus (GDM) affects up to 20% of pregnancies, and almost half of the women affected progress to type 2 diabetes later in life, making GDM the most significant risk factor for the development of future type 2 diabetes. An accurate prediction of future type 2 diabetes risk in the early postpartum period after GDM would allow for timely interventions to prevent or delay type 2 diabetes. In addition, new targets for interventions may be revealed by understanding the underlying pathophysiology of the transition from GDM to type 2 diabetes. The aim of this study is to identify both a predictive signature and early-stage pathophysiology of the transition from GDM to type 2 diabetes. METHODS: We used a well-characterised prospective cohort of women with a history of GDM pregnancy, all of whom were enrolled at 6-9 weeks postpartum (baseline), were confirmed not to have diabetes via 2 h 75 g OGTT and tested anually for type 2 diabetes on an ongoing basis (2 years of follow-up). A large-scale targeted lipidomic study was implemented to analyse ~1100 lipid metabolites in baseline plasma samples using a nested pair-matched case-control design, with 55 incident cases matched to 85 non-case control participants. The relationships between the concentrations of baseline plasma lipids and respective follow-up status (either type 2 diabetes or no type 2 diabetes) were employed to discover both a predictive signature and the underlying pathophysiology of the transition from GDM to type 2 diabetes. In addition, the underlying pathophysiology was examined in vivo and in vitro. RESULTS: Machine learning optimisation in a decision tree format revealed a seven-lipid metabolite type 2 diabetes predictive signature with a discriminating power (AUC) of 0.92 (87% sensitivity, 93% specificity and 91% accuracy). The signature was highly robust as it includes 45-fold cross-validation under a high confidence threshold (1.0) and binary output, which together minimise the chance of data overfitting and bias selection. Concurrent analysis of differentially expressed lipid metabolite pathways uncovered the upregulation of α-linolenic/linoleic acid metabolism (false discovery rate [FDR] 0.002) and fatty acid biosynthesis (FDR 0.005) and the downregulation of sphingolipid metabolism (FDR 0.009) as being strongly associated with the risk of developing future type 2 diabetes. Focusing specifically on sphingolipids, the downregulation of sphingolipid metabolism using the pharmacological inhibitors fumonisin B1 (FB1) and myriocin in mouse islets and Min6 K8 cells (a pancreatic beta-cell like cell line) significantly impaired glucose-stimulated insulin secretion but had no significant impact on whole-body glucose homeostasis or insulin sensitivity. CONCLUSIONS/INTERPRETATION: We reveal a novel predictive signature and associate reduced sphingolipids with the pathophysiology of transition from GDM to type 2 diabetes. Attenuating sphingolipid metabolism in islets impairs glucose-stimulated insulin secretion.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Khan SR, Mohan H, Liu Y, et al. The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes. Diabetologia. 2019. PMID: 30645667. doi:10.1007/s00125-018-4800-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。